Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA
Authors
Keywords
-
Journal
CANCER
Volume 124, Issue 10, Pages 2115-2124
Publisher
Wiley
Online
2018-03-08
DOI
10.1002/cncr.31314
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma
- (2017) Tyler J. Moss et al. EUROPEAN UROLOGY
- Pertuzumab plus trastuzumab for HER2-positive metastatic urothelial cancer (mUC): Preliminary data from MyPathway.
- (2017) Alan Haruo Bryce et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2–Positive Metastatic Bladder Cancer
- (2017) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
- (2017) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
- (2017) Christophe Massard et al. Cancer Discovery
- Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications
- (2017) Andrew W. Hahn et al. Oncotarget
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations
- (2016) Noura J. Choudhury et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- (2016) Christophe Massard et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Bladder cancer
- (2016) Ashish M Kamat et al. LANCET
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
- (2016) Padmanee Sharma et al. LANCET ONCOLOGY
- Polyclonal SecondaryFGFR2Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
- (2016) Lipika Goyal et al. Cancer Discovery
- Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations
- (2015) Jeffrey S. Ross et al. CANCER
- Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2
- (2015) Stéphane Oudard et al. EUROPEAN JOURNAL OF CANCER
- Genomic Characterization of Upper Tract Urothelial Carcinoma
- (2015) John P. Sfakianos et al. EUROPEAN UROLOGY
- European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update
- (2015) Morgan Rouprêt et al. EUROPEAN UROLOGY
- Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
- (2015) Christophe Le Tourneau et al. LANCET ONCOLOGY
- Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
- (2015) M. Russo et al. Cancer Discovery
- Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
- (2015) Richard B. Lanman et al. PLoS One
- PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes
- (2015) Filip Janku et al. Oncotarget
- Emerging protein kinase inhibitors for non-small cell lung cancer
- (2013) Stephen V Liu et al. EXPERT OPINION ON EMERGING DRUGS
- Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment
- (2013) Grit S. Herter-Sprie et al. Frontiers in Oncology
- Integrated Genomic and Gene Expression Profiling Identifies Two Major Genomic Circuits in Urothelial Carcinoma
- (2012) David Lindgren et al. PLoS One
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma
- (2009) Christian Wülfing et al. CANCER
- Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration
- (2009) Vitaly Margulis et al. CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started